For healthcare professionals only


Novo Nordisk pays $58.7m to settle claims of mis-selling liraglutide

BMJ 2017; 358 doi: (Published 08 September 2017) Cite this as: BMJ 2017;358:j4214

Who is making misleading claims?

Dear Editors

As much as I abhor misleading marketing and the idea of alleged promotion of the off-label use of liraglutide in patients who did not have type 2 diabetes, I wonder if the BMJ is also guilty of making some misleading claims in the article in reporting that:

"sales of liraglutide, which totalled $843bn last year. "

While I acknowledge the currency of this quote was not stated, I am curious to know where the sales statistics of 840 billion dollars come from.

Afterall it wasn't long ago they were aspiring to hit annual global liraglutide sales of USD1bn.

Competing interests: No competing interests

11 September 2017
Shyan Goh
Orthopaedic Surgeon